<DOC>
	<DOCNO>NCT02937662</DOCNO>
	<brief_summary>In multi-center , randomize , open-label , prospective clinical trial , total 60 relapsed/refractory AML patient randomize 2 group . In experimental arm , patient receive IAC regimen . In control arm , patient receive physician-directed regimen . The primary end point complete remission rate .</brief_summary>
	<brief_title>Efficacy Idarubicin , Cytarabine Cyclophosphamide ( IAC ) Regimen Relapsed/Refractory AML</brief_title>
	<detailed_description>In multi-center , randomize , open-label , prospective clinical trial , total 60 relapsed/refractory AML patient randomize 2 group . Patients IAC arm receive therapy consist idarubicin 10 mg/㎡/d day 1-3 , cytarabine 100mg/㎡/d day 1-7 cyclophosphamide dose 350mg/㎡/d second day fifth day . In control arm , patient receive physician-directed regimen include fludarabine , cytarabine with/without granulocyte stimulate factor ( FLA±G ) regimen , cytarabine plus daunorubicin ( DA）regimen , decitabine , aclacinomycin cytarabine ( decitabine plus AA ) regimen AA regimen plus granulocyte stimulating factor . All regimen control arm contain cyclophosphamide . The primary end point complete remission . The second end point include overall survival , relapse-free survival time treatment failure .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>1 . Age le 60 year old ; 2 . Patients meet diagnostic criterion ( WHO 2008 criterion ) AML ( except APL subtypes ) . 3 . Patients confirm pathologic diagnosis AML relapse refractory . 4 . Patients ECOG score ≤ 2 ; 5 . Adult patient willing participate study sign inform consent immediate family . Patients 18 year old willing participate legal guardian sign inform consent . 1 . Patients receive reinduction therapy include cyclophosphamide exclude . However , patient receive regimen include cyclophosphamide relapse eligible . 2 . Patients blood disease ( example , haemophiliac ) exclude . 3 . Relapsed patient extramedullary leukemia ; 4 . After allogeneic hematopoietic stem cell transplantation ; 5 . With mutation breakpoint cluster regionAbelson ( BCRABL ) fusion gene need tyrosine kinase inhibitor therapy ; 6 . Acute panmyelosis myelofibrosis myeloid sarcoma patient ; 7 . Had malignant tumor need treatment ; 8 . Had active cardiovascular disease ; 9 . Patients factor consider unsuitable participate study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>